Compunet Clinical Laboratories LLC
Compunet Clinical Laboratories LLC was paid $34.27M by Medicaid between Jan 2018 and Dec 2024, across 356 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 8.8% of everything it billed.
MORAINE, OH 45439
Next to other Clinical Medical Laboratory providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 423,275 | $3.81M | |
| 2019 | 406,411 | $3.93M | |
| 2020 | 475,348 | $6.13M | |
| 2021 | 557,337 | $6.04M | |
| 2022 | 588,821 | $5.04M | |
| 2023 | 601,269 | $4.93M | |
| 2024incomplete | 531,917 | $4.40M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.8% | 43,104 | 41,324 | $3.02M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.9% | 91,199 | 85,196 | $2.03M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.7% | 90,889 | 85,100 | $1.97M |
| 80053 | Comprehensive metabolic panel | 4.5% | 256,646 | 226,098 | $1.54M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 4.5% | 75,832 | 69,845 | $1.53M |
| 84443 | Thyroid stimulating hormone (TSH) | 4.1% | 155,366 | 143,482 | $1.40M |
| 80061 | Lipid panel | 3.4% | 165,437 | 153,124 | $1.18M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.4% | 37,488 | 27,094 | $1.18M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 261,425 | 220,839 | $1.15M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.2% | 49,218 | 46,172 | $757K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.1% | 58,417 | 53,376 | $719K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.9% | 18,941 | 14,334 | $667K |
344 more codes
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.6% | 36,610 | $551K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 361,084 | $535K |
| 87902 | 1.4% | 3,576 | $489K | |
| 87481 | 1.4% | 18,170 | $482K | |
| 81513 | 1.4% | 8,559 | $470K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 96,377 | $457K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.3% | 2,525 | $456K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 11,010 | $450K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.3% | 23,061 | $449K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.3% | 12,502 | $449K |
| 86803 | 1.3% | 49,517 | $434K | |
| 86481 | 1.1% | 8,078 | $365K | |
| 84439 | 1.1% | 76,646 | $361K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 19,886 | $359K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.0% | 72,054 | $346K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,389 | $315K |
| 87522 | Neg quan hep c or qual rna | <1% | 13,659 | $276K |
| 82728 | <1% | 36,640 | $270K | |
| 82607 | <1% | 36,995 | $257K | |
| 87088 | <1% | 50,101 | $254K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,496 | $231K |
| 85027 | <1% | 56,070 | $218K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 48,504 | $217K |
| 87536 | <1% | 4,521 | $200K | |
| 84153 | <1% | 18,088 | $183K | |
| 80081 | <1% | 4,560 | $172K | |
| 83550 | <1% | 35,863 | $171K | |
| 87070 | <1% | 30,624 | $170K | |
| 80055 | <1% | 5,337 | $168K | |
| 88341 | <1% | 2,076 | $167K | |
| 87340 | <1% | 26,848 | $164K | |
| 86480 | <1% | 5,106 | $156K | |
| 80074 | <1% | 8,365 | $151K | |
| 83970 | <1% | 7,964 | $151K | |
| 82746 | <1% | 27,024 | $151K | |
| 84403 | <1% | 10,176 | $144K | |
| 88342 | <1% | 3,096 | $143K | |
| 83540 | <1% | 37,618 | $142K | |
| 84702 | <1% | 14,469 | $132K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 816 | $129K |
| 86003 | <1% | 6,224 | $116K | |
| 87186 | <1% | 21,694 | $114K | |
| 87077 | <1% | 21,757 | $109K | |
| 86235 | <1% | 4,456 | $105K | |
| 87480 | <1% | 8,681 | $105K | |
| 87510 | <1% | 8,659 | $103K | |
| 86038 | <1% | 14,076 | $101K | |
| 88365 | <1% | 975 | $99K | |
| 86592 | <1% | 38,249 | $99K | |
| 87660 | <1% | 8,706 | $91K | |
| 82570 | <1% | 31,512 | $89K | |
| 84481 | <1% | 8,974 | $86K | |
| 83001 | <1% | 6,635 | $82K | |
| 84146 | <1% | 6,883 | $81K | |
| 88141 | <1% | 5,575 | $81K | |
| 80069 | <1% | 18,787 | $81K | |
| 87653 | <1% | 4,345 | $75K | |
| 86704 | <1% | 10,338 | $73K | |
| 86706 | <1% | 11,112 | $72K | |
| 80076 | <1% | 14,972 | $71K | |
| 81001 | <1% | 38,218 | $68K | |
| 86762 | <1% | 7,814 | $68K | |
| 82670 | <1% | 4,262 | $68K | |
| 87631 | <1% | 1,090 | $67K | |
| 83735 | <1% | 19,486 | $65K | |
| 82043 | <1% | 20,252 | $64K | |
| 82784 | <1% | 7,699 | $63K | |
| 82105 | <1% | 6,467 | $61K | |
| 80050 | General health panel | <1% | 10,921 | $60K |
| 82950 | <1% | 18,383 | $59K | |
| 84144 | <1% | 4,876 | $58K | |
| 85610 | <1% | 21,947 | $57K | |
| 81596 | <1% | 1,872 | $57K | |
| 84402 | <1% | 3,947 | $56K | |
| 86696 | <1% | 5,519 | $54K | |
| 86708 | <1% | 7,169 | $53K | |
| 86140 | <1% | 20,873 | $53K | |
| 83516 | <1% | 6,111 | $52K | |
| 87486 | <1% | 2,487 | $51K | |
| 87581 | <1% | 2,487 | $51K | |
| 87529 | <1% | 1,918 | $51K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,140 | $50K |
| 87147 | <1% | 13,154 | $48K | |
| 82248 | <1% | 19,741 | $47K | |
| 83880 | <1% | 2,747 | $47K | |
| 83020 | <1% | 5,844 | $47K | |
| 82951 | <1% | 7,914 | $46K | |
| 86360 | <1% | 1,673 | $46K | |
| 83655 | <1% | 5,093 | $42K | |
| 83002 | <1% | 3,895 | $42K | |
| 86160 | <1% | 2,913 | $39K | |
| 87563 | <1% | 2,531 | $38K | |
| 85652 | <1% | 23,890 | $37K | |
| 86850 | <1% | 7,370 | $36K | |
| 84550 | <1% | 14,258 | $36K | |
| 83525 | <1% | 5,127 | $35K | |
| 83013 | <1% | 1,007 | $35K | |
| 84450 | <1% | 12,200 | $35K | |
| 86431 | <1% | 9,944 | $34K | |
| 84460 | <1% | 11,322 | $34K | |
| 83690 | <1% | 8,343 | $32K | |
| 86334 | <1% | 2,890 | $32K | |
| 86376 | <1% | 3,696 | $31K | |
| 86147 | <1% | 835 | $31K | |
| 86695 | <1% | 5,531 | $31K | |
| 82565 | <1% | 11,752 | $31K | |
| 87517 | <1% | 1,243 | $29K | |
| 83520 | <1% | 1,855 | $28K | |
| 84425 | <1% | 2,549 | $28K | |
| 86146 | <1% | 760 | $28K | |
| 88360 | <1% | 395 | $28K | |
| 84436 | <1% | 11,424 | $25K | |
| 82550 | <1% | 6,590 | $25K | |
| 80164 | <1% | 4,113 | $24K | |
| 82378 | <1% | 2,484 | $23K | |
| 86317 | <1% | 2,677 | $23K | |
| 84480 | <1% | 3,405 | $23K | |
| 84156 | <1% | 11,665 | $23K | |
| 86225 | <1% | 2,863 | $22K | |
| 82140 | <1% | 3,014 | $22K | |
| 86039 | <1% | 3,443 | $22K | |
| 87625 | <1% | 2,136 | $22K | |
| 82785 | <1% | 2,452 | $22K | |
| 86800 | <1% | 2,639 | $22K | |
| 88364 | <1% | 308 | $22K | |
| 86359 | <1% | 1,097 | $22K | |
| 86255 | <1% | 2,829 | $22K | |
| 84165 | <1% | 4,015 | $21K | |
| 87799 | <1% | 600 | $21K | |
| 86769 | <1% | 664 | $20K | |
| 80361 | <1% | 1,518 | $20K | |
| 86200 | <1% | 2,692 | $20K | |
| 80197 | <1% | 4,269 | $20K | |
| 87449 | <1% | 2,691 | $20K | |
| 88142 | <1% | 1,719 | $20K | |
| 83615 | <1% | 5,922 | $19K | |
| 82533 | <1% | 2,094 | $19K | |
| 86787 | <1% | 2,581 | $19K | |
| 84100 | <1% | 7,641 | $19K | |
| 80349 | <1% | 2,370 | $18K | |
| 88185 | <1% | 65 | $17K | |
| 80346 | <1% | 1,132 | $17K | |
| 87081 | <1% | 4,338 | $17K | |
| 84590 | <1% | 2,634 | $16K | |
| 87427 | <1% | 2,387 | $16K | |
| 86258 | <1% | 2,375 | $16K | |
| 84134 | <1% | 1,908 | $15K | |
| 83993 | <1% | 1,422 | $15K | |
| 86364 | <1% | 2,789 | $15K | |
| 86361 | <1% | 1,084 | $14K | |
| 87493 | <1% | 1,034 | $14K | |
| 86300 | <1% | 1,486 | $14K | |
| 82274 | <1% | 1,557 | $14K | |
| 82627 | <1% | 1,323 | $14K | |
| 84703 | <1% | 2,992 | $13K | |
| 82150 | <1% | 4,558 | $13K | |
| 80348 | <1% | 1,552 | $13K | |
| 86709 | <1% | 1,933 | $13K | |
| 83883 | <1% | 1,322 | $13K | |
| 87045 | <1% | 2,389 | $12K | |
| 84075 | <1% | 6,667 | $12K | |
| 85018 | <1% | 8,838 | $12K | |
| 84520 | <1% | 6,574 | $12K | |
| 82247 | <1% | 5,604 | $12K | |
| 87329 | <1% | 1,825 | $12K | |
| 86060 | <1% | 2,699 | $12K | |
| 82977 | <1% | 3,261 | $12K | |
| 87046 | <1% | 2,409 | $12K | |
| 86780 | <1% | 1,670 | $12K | |
| 87328 | <1% | 1,667 | $11K | |
| 83521 | <1% | 958 | $11K | |
| 85730 | <1% | 3,998 | $11K | |
| 86849 | <1% | 445 | $11K | |
| 82525 | <1% | 1,674 | $11K | |
| 85014 | <1% | 7,917 | $11K | |
| 86231 | <1% | 1,661 | $11K | |
| 84155 | <1% | 5,749 | $10K | |
| 84630 | <1% | 1,807 | $10K | |
| 86381 | <1% | 875 | $10K | |
| 82040 | <1% | 4,673 | $10K | |
| 80354 | <1% | 1,211 | $10K | |
| 84478 | <1% | 3,887 | $9K | |
| 82390 | <1% | 1,502 | $9K | |
| 87324 | <1% | 1,727 | $9K | |
| 82677 | <1% | 563 | $9K | |
| 82652 | <1% | 487 | $9K | |
| 86901 | <1% | 4,674 | $9K | |
| 80051 | <1% | 2,804 | $9K | |
| 82310 | <1% | 3,870 | $9K | |
| 86665 | <1% | 444 | $8K | |
| 81003 | <1% | 6,876 | $8K | |
| 80178 | <1% | 2,417 | $8K | |
| 86705 | <1% | 1,088 | $8K | |
| 84154 | <1% | 881 | $8K | |
| 86900 | <1% | 4,740 | $8K | |
| 87512 | <1% | 297 | $8K | |
| 86021 | <1% | 955 | $8K | |
| 84270 | <1% | 706 | $7K | |
| 85045 | <1% | 3,635 | $7K | |
| 80353 | <1% | 1,085 | $7K | |
| 84681 | <1% | 684 | $7K | |
| 80365 | <1% | 888 | $7K | |
| 80324 | <1% | 1,112 | $7K | |
| 86765 | <1% | 895 | $7K | |
| 87210 | <1% | 2,505 | $7K | |
| 83718 | <1% | 2,010 | $6K | |
| 86015 | <1% | 1,268 | $6K | |
| 80362 | <1% | 399 | $6K | |
| 86403 | <1% | 990 | $6K | |
| 81025 | <1% | 1,450 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 610 | $6K |
| 82465 | <1% | 2,992 | $6K | |
| 86735 | <1% | 737 | $6K | |
| 86336 | <1% | 541 | $5K | |
| 0001A | <1% | 62 | $5K | |
| 86301 | <1% | 582 | $5K | |
| 84207 | <1% | 357 | $5K | |
| 82103 | <1% | 778 | $5K | |
| 86707 | <1% | 776 | $5K | |
| 82947 | <1% | 2,657 | $5K | |
| 86141 | <1% | 631 | $4K | |
| 80321 | <1% | 422 | $4K | |
| 87634 | <1% | 118 | $4K | |
| 81241 | <1% | 150 | $4K | |
| 84482 | <1% | 464 | $4K | |
| 86304 | <1% | 354 | $4K | |
| 82672 | <1% | 349 | $4K | |
| 88112 | <1% | 145 | $4K | |
| 84132 | <1% | 1,761 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 16 | $4K |
| 87350 | <1% | 588 | $4K | |
| 82653 | <1% | 388 | $4K | |
| 85379 | <1% | 740 | $4K | |
| 83921 | <1% | 326 | $3K | |
| 82024 | <1% | 190 | $3K | |
| 83519 | <1% | 269 | $3K | |
| 86664 | <1% | 343 | $3K | |
| 86036 | <1% | 508 | $3K | |
| 87102 | <1% | 592 | $3K | |
| 85613 | <1% | 567 | $3K | |
| 87497 | <1% | 177 | $3K | |
| 86148 | <1% | 593 | $3K | |
| 81240 | <1% | 107 | $3K | |
| 83010 | <1% | 432 | $3K | |
| 86593 | <1% | 1,060 | $3K | |
| 83090 | <1% | 572 | $3K | |
| 0002A | <1% | 48 | $3K | |
| 83721 | <1% | 1,263 | $2K | |
| 82542 | <1% | 217 | $2K | |
| 84295 | <1% | 1,312 | $2K | |
| 86677 | <1% | 334 | $2K | |
| 85670 | <1% | 566 | $2K | |
| 83498 | <1% | 107 | $2K | |
| 88184 | <1% | 65 | $2K | |
| 86812 | <1% | 95 | $2K | |
| 84166 | <1% | 185 | $2K | |
| 85660 | <1% | 434 | $1K | |
| 80177 | <1% | 329 | $1K | |
| 84432 | <1% | 191 | $1K | |
| 81270 | <1% | 46 | $1K | |
| 81050 | <1% | 861 | $1K | |
| 87650 | <1% | 104 | $1K | |
| 86682 | <1% | 191 | $1K | |
| 85347 | <1% | 565 | $1K | |
| 87338 | <1% | 203 | $1K | |
| 85049 | <1% | 700 | $1K | |
| 85004 | <1% | 382 | $1K | |
| 82374 | <1% | 948 | $1K | |
| 82088 | <1% | 58 | $1K | |
| 82435 | <1% | 925 | $1K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 376 | $1K |
| 84445 | <1% | 59 | $982.23 | |
| 87220 | <1% | 383 | $961.16 | |
| 80159 | <1% | 182 | $877.23 | |
| 87205 | <1% | 343 | $802.96 | |
| 87209 | <1% | 60 | $740.25 | |
| 80359 | <1% | 188 | $733.57 | |
| 88304 | <1% | 41 | $729.85 | |
| 83930 | <1% | 174 | $710.08 | |
| 85306 | <1% | 96 | $694.50 | |
| 82952 | <1% | 295 | $691.72 | |
| 85240 | <1% | 70 | $683.71 | |
| 86870 | <1% | 45 | $624.49 | |
| 80360 | <1% | 88 | $623.97 | |
| 87341 | <1% | 118 | $609.97 | |
| 80320 | <1% | 56 | $563.74 | |
| 80156 | <1% | 88 | $527.92 | |
| 80367 | <1% | 83 | $512.42 | |
| 85300 | <1% | 110 | $507.35 | |
| 82104 | <1% | 75 | $506.35 | |
| 85303 | <1% | 88 | $490.55 | |
| 86618 | <1% | 42 | $483.40 | |
| 85307 | <1% | 93 | $480.33 | |
| 80414 | <1% | 12 | $439.87 | |
| 80355 | <1% | 53 | $433.48 | |
| 82668 | <1% | 47 | $427.57 | |
| 84244 | <1% | 42 | $427.45 | |
| 88189 | <1% | 12 | $423.98 | |
| 84466 | <1% | 99 | $412.21 | |
| 86308 | <1% | 117 | $398.22 | |
| 85705 | <1% | 82 | $393.37 | |
| 86341 | <1% | 35 | $377.37 | |
| 87177 | <1% | 60 | $376.33 | |
| 81015 | <1% | 768 | $375.42 | |
| 87184 | <1% | 90 | $358.89 | |
| 83014 | <1% | 64 | $302.81 | |
| 80185 | <1% | 44 | $258.63 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 5,201 | $246.66 |
| 84597 | <1% | 25 | $198.96 | |
| 82330 | <1% | 30 | $176.41 | |
| 85048 | <1% | 329 | $169.34 | |
| 83992 | <1% | 15 | $151.90 | |
| 82656 | <1% | 25 | $146.00 | |
| 89055 | <1% | 47 | $139.26 | |
| 85597 | <1% | 14 | $137.64 | |
| 84300 | <1% | 55 | $134.09 | |
| 80175 | <1% | 26 | $123.07 | |
| 85305 | <1% | 31 | $118.62 | |
| 80162 | <1% | 22 | $107.81 | |
| 80373 | <1% | 15 | $106.54 | |
| 80377 | <1% | 15 | $106.54 | |
| 87040 | <1% | 18 | $100.94 | |
| 82164 | <1% | 13 | $99.01 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 567 | $95.97 |
| 84446 | <1% | 15 | $93.20 | |
| 80345 | <1% | 15 | $91.48 | |
| 36416 | <1% | 63 | $89.08 | |
| 85041 | <1% | 232 | $79.02 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 4,901 | $74.67 |
| 87076 | <1% | 13 | $73.28 | |
| 85732 | <1% | 18 | $66.63 | |
| 87101 | <1% | 15 | $61.88 | |
| 82575 | <1% | 13 | $55.42 | |
| 80374 | <1% | 15 | $54.86 | |
| 85420 | <1% | 13 | $43.37 | |
| 85007 | <1% | 110 | $39.72 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 265 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 1,663 | $0.00 |
| P3001 | Screening papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician | 0% | 25 | $0.00 |
| 80375 | 0% | 263 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 228 | $0.00 |
| 81329 | 0% | 14 | $0.00 | |
| 81206 | 0% | 12 | $0.00 | |
| 81291 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Mains'l Florida, INC. | Brooklyn Park, MN | $996.80M |
| Mains'l Fiscal Support Entity | Brooklyn Park, MN | $3.23M |
| Anew Home Health, LLC | Indianapolis, IN | $813K |
| Compunet Clinical Laboratories LLC | Dayton, OH | $64K |
| Compunet Clinical Laboratories, LLC | Dayton, OH | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.